First patients dosed in trial of radioactive antibody for prostate, other cancers

The first three patients have been dosed in a clinical trial evaluating the safety and tolerability of MILGa, a radioactive antibody designed to seek out and destroy cancerous tumors in advanced prostate, bladder, and pancreatic cancer.

The patients — two with pancreatic cancer and one with prostate cancer — have completed a one-month follow-up, and no treatment-related side effects were reported, according to a press release from the treatment’s developer. Read more.